Cargando…
Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray
Chronic itch severely reduces the quality of life of patients. Electroacupuncture (EA) is widely used to treat chronic itch. However, the underlying mechanism of this therapeutic action of EA is largely unknown. Cannabinoid CB1 receptors in the ventrolateral periaqueductal gray (vlPAG) mediate the a...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483028/ https://www.ncbi.nlm.nih.gov/pubmed/36133809 http://dx.doi.org/10.3389/fphar.2022.931600 |
_version_ | 1784791582815289344 |
---|---|
author | Ge, Wen-Qiang Zhan-Mu, Ou-Yang Chen, Chao Zhang, Hong Wang, Xiao-Yu Liu, Xin Li, Li Lan, Yu-Ye Li, Chen-Nan Sun, Jia-Can Shi, Run-Lin Dou, Zi-Yue Pan, Hui-Lin Li, Hong-Ping Jing, Xiang-Hong Li, Man |
author_facet | Ge, Wen-Qiang Zhan-Mu, Ou-Yang Chen, Chao Zhang, Hong Wang, Xiao-Yu Liu, Xin Li, Li Lan, Yu-Ye Li, Chen-Nan Sun, Jia-Can Shi, Run-Lin Dou, Zi-Yue Pan, Hui-Lin Li, Hong-Ping Jing, Xiang-Hong Li, Man |
author_sort | Ge, Wen-Qiang |
collection | PubMed |
description | Chronic itch severely reduces the quality of life of patients. Electroacupuncture (EA) is widely used to treat chronic itch. However, the underlying mechanism of this therapeutic action of EA is largely unknown. Cannabinoid CB1 receptors in the ventrolateral periaqueductal gray (vlPAG) mediate the analgesic effect of EA. Using a dry skin-induced itch model in mice, we determined whether EA treatment reduces chronic itch via CB1 receptors in the vlPAG. We showed that the optimal inhibitory effect of EA on chronic itch was achieved at the high frequency and high intensity (100 Hz and 3 mA) at “Quchi” (LI11) and “Hegu” (LI14) acupoints, which are located in the same spinal dermatome as the cervical skin lesions. EA reversed the increased expression of CB1 receptors in the vlPAG and decreased the concentration of 5-hydroxytryptamine (5-HT) in the medulla oblongata and the expression of gastrin-releasing peptide receptors (GRPR) in the cervical spinal cord. Furthermore, knockout of CB1 receptors on GABAergic neurons in the vlPAG attenuated scratching behavior and the 5-HT concentration in the medulla oblongata. In contrast, knockout of CB1 receptors on glutamatergic neurons in the vlPAG blocked the antipruritic effects of EA and the inhibitory effect of EA on the 5-HT concentration in the medulla oblongata. Our findings suggest that EA treatment reduces chronic itch by activation of CB1 receptors on glutamatergic neurons and inhibition of CB1 receptors on GABAergic neurons in the vlPAG, thereby inhibiting the 5-HT release from the medulla oblongata to GRPR-expressing neurons in the spinal cord. Our findings suggest that EA attenuates chronic itch via activating CB1 receptors expressed on glutamatergic neurons and downregulating CB1 receptors on GABAergic neurons in the vlPAG, leading to the reduction in 5-HT release in the rostroventral medulla and GRPR signaling in the spinal cord. Our study not only advances our understanding of the mechanisms of the therapeutic effect of EA on chronic itch but also guides the selection of optimal parameters and acupoints of EA for treating chronic itch. |
format | Online Article Text |
id | pubmed-9483028 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94830282022-09-20 Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray Ge, Wen-Qiang Zhan-Mu, Ou-Yang Chen, Chao Zhang, Hong Wang, Xiao-Yu Liu, Xin Li, Li Lan, Yu-Ye Li, Chen-Nan Sun, Jia-Can Shi, Run-Lin Dou, Zi-Yue Pan, Hui-Lin Li, Hong-Ping Jing, Xiang-Hong Li, Man Front Pharmacol Pharmacology Chronic itch severely reduces the quality of life of patients. Electroacupuncture (EA) is widely used to treat chronic itch. However, the underlying mechanism of this therapeutic action of EA is largely unknown. Cannabinoid CB1 receptors in the ventrolateral periaqueductal gray (vlPAG) mediate the analgesic effect of EA. Using a dry skin-induced itch model in mice, we determined whether EA treatment reduces chronic itch via CB1 receptors in the vlPAG. We showed that the optimal inhibitory effect of EA on chronic itch was achieved at the high frequency and high intensity (100 Hz and 3 mA) at “Quchi” (LI11) and “Hegu” (LI14) acupoints, which are located in the same spinal dermatome as the cervical skin lesions. EA reversed the increased expression of CB1 receptors in the vlPAG and decreased the concentration of 5-hydroxytryptamine (5-HT) in the medulla oblongata and the expression of gastrin-releasing peptide receptors (GRPR) in the cervical spinal cord. Furthermore, knockout of CB1 receptors on GABAergic neurons in the vlPAG attenuated scratching behavior and the 5-HT concentration in the medulla oblongata. In contrast, knockout of CB1 receptors on glutamatergic neurons in the vlPAG blocked the antipruritic effects of EA and the inhibitory effect of EA on the 5-HT concentration in the medulla oblongata. Our findings suggest that EA treatment reduces chronic itch by activation of CB1 receptors on glutamatergic neurons and inhibition of CB1 receptors on GABAergic neurons in the vlPAG, thereby inhibiting the 5-HT release from the medulla oblongata to GRPR-expressing neurons in the spinal cord. Our findings suggest that EA attenuates chronic itch via activating CB1 receptors expressed on glutamatergic neurons and downregulating CB1 receptors on GABAergic neurons in the vlPAG, leading to the reduction in 5-HT release in the rostroventral medulla and GRPR signaling in the spinal cord. Our study not only advances our understanding of the mechanisms of the therapeutic effect of EA on chronic itch but also guides the selection of optimal parameters and acupoints of EA for treating chronic itch. Frontiers Media S.A. 2022-09-05 /pmc/articles/PMC9483028/ /pubmed/36133809 http://dx.doi.org/10.3389/fphar.2022.931600 Text en Copyright © 2022 Ge, Zhan-Mu, Chen, Zhang, Wang, Liu, Li, Lan, Li, Sun, Shi, Dou, Pan, Li, Jing and Li. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Ge, Wen-Qiang Zhan-Mu, Ou-Yang Chen, Chao Zhang, Hong Wang, Xiao-Yu Liu, Xin Li, Li Lan, Yu-Ye Li, Chen-Nan Sun, Jia-Can Shi, Run-Lin Dou, Zi-Yue Pan, Hui-Lin Li, Hong-Ping Jing, Xiang-Hong Li, Man Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray |
title | Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray |
title_full | Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray |
title_fullStr | Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray |
title_full_unstemmed | Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray |
title_short | Electroacupuncture reduces chronic itch via cannabinoid CB1 receptors in the ventrolateral periaqueductal gray |
title_sort | electroacupuncture reduces chronic itch via cannabinoid cb1 receptors in the ventrolateral periaqueductal gray |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9483028/ https://www.ncbi.nlm.nih.gov/pubmed/36133809 http://dx.doi.org/10.3389/fphar.2022.931600 |
work_keys_str_mv | AT gewenqiang electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT zhanmuouyang electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT chenchao electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT zhanghong electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT wangxiaoyu electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT liuxin electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT lili electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT lanyuye electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT lichennan electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT sunjiacan electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT shirunlin electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT douziyue electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT panhuilin electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT lihongping electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT jingxianghong electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray AT liman electroacupuncturereduceschronicitchviacannabinoidcb1receptorsintheventrolateralperiaqueductalgray |